Clinical Trial Update: A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MM-111 in combination with paclitaxel and trastuzumab for HER2-positive distal esophagus, gastroesophageal junction, and stomach canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer
• Stomach Cancer

Drugs mentioned

• MM-111
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: HER-2 Gene Amplification, Esophagus Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-06-22